Replimune to Resubmit Melanoma Drug After FDA Leadership Change
Replimune is resubmitting its melanoma drug to the FDA for approval after two rejections, following a leadership change at the agency.
Markets, economy, and policy news for investors.
Investor topic hub
Market-moving news across stocks, bonds, currencies, private credit, capital markets, and investor sentiment.